.. Traitement-du-cancer-de-la-prostate-résistant-À-la-castration, 34 I-7-6-1) Mécanismes moléculaires impliqués dans le phénomène d'hormonorésistance, p.35

P. Prostvac-vf®:-un-vaccin-viral-ciblant-le, 46 II-1-2-3-1) Mécanisme d'action du vaccin 47 II-1-2-3-2) Essais cliniques, 48 II-1-2-3-3) PROSTVAC en combinaison avec les thérapies standards, p.49

.. Nouvelles-molécules-d-'hormonothérapies, 55 II-2-1) acétate d'abiraterone (ZYTIGA®) 55 II-2-1-1) Population cible 56 II-2-1-2) 56 II-2-1-3) Essais cliniques 57 II-2-1-4) Effets indésirables, pp.58-60

.. Inhibiteur-des-clusterines-custirsen, 74 II-4-5-1) Rôle des clusterines dans le cancer de la prostate 74 II-4-5-2) Cibler les clusterines avec une technologie, p.76

N. Traitements-des-métastases-osseuses-dans-le-cancer-de-la-prostate and .. , 77 II-5-1) Le denosumab : un anticorps monoclonal anti-ostéoclastique 78 II-5-1-1) Mécanisme d'action, p.78

L. Médicament-radiopharmaceutique-ciblant-l-'os and .. , 79 II-5-2-1) Posologie mode d'administration, p.82

.. La-castration, 82 II-6-1) Options thérapeutiques chez les patients chimio naïfs, pp.82-88

B. 1. Seisen, T. Rouprêt, M. Faix, and A. , La prostate : une glande au carrefour uro-g??nital, Progr??s en Urologie, vol.22, pp.2-6, 2012.
DOI : 10.1016/S1166-7087(12)70028-3

P. Lonergan and D. Tindall, Androgen receptor signaling in prostate cancer development and progression, J Carcinog aout, vol.10, issue.20, pp.22-41, 2011.

H. Autorité and D. Santé, Cancer de la prostate -Identification des facteurs de risque et pertinence d'un dépistage par dosage de l'antigène spécifique prostatique (PSA) de population d'hommes à haut risque?, Février, 2012.

J. Poirier and . L-'hypertrophie-bénigne-de-la-prostate-et-son-traitement-médicamenteux, Disponible sur: http://scd.uhp-nancy.fr/docnum/SCDPHA_T_2009_POIRIER_JOSEPHINE.pdf 10. Boissier R. L'antigène spécifique de la prostate ou PSA, Prog Urol, vol.21, issue.11, pp.798-800, 2009.

P. Marko, D. Schmid, and M. Koller, Antigène spécifique de la prostate (PSA) : dosage en connaissance de cause, Forum Med Suisse, vol.9, pp.28-37, 2009.

N. Mottet, P. Bastian, J. Bellmunt, M. Bolla, S. Joniau et al., Guidelines on prostate cancer, 2014.

W. Catalona, A. Partin, and K. Slawin, Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease, JAMA, vol.279, issue.19, pp.1542-1549, 1998.
DOI : 10.1001/jama.279.19.1542

A. El-hakim and S. Moussa, CUA guidelines on prostate biopsy methodology, Canadian Urological Association Journal, vol.4, issue.2, pp.89-94, 2010.
DOI : 10.5489/cuaj.797

URL : http://europepmc.org/articles/pmc2845759?pdf=render

R. Briffaux, État de l'art: antibioprophylaxie pour les biopsies de prostate: State of art: antibioprophylaxis for biopsy of the prostate, Prog Urol, vol.18, issue.3, pp.15-18, 2008.

A. Francaise-d-'urologie and . Qu-'est-ce-qu-'une-biopsie-echoguidée-de-la-prostate, Disponible sur: http://www.urofrance.org/nc/lurologiegrandpublic/fiches-patient/resultats-de-la-recherche/html/biopsie-echoguidee-de-laprostate .html 17. Ploussard G, de la Taille A. Test urinaire PCA3 en pratique clinique, Prog Urol, vol.19, issue.3, pp.86-901, 2008.

D. Hessels, K. Gunnewiek, J. Van-oort, I. Karthaus, H. Van-leenders et al., DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer, European Urology, vol.44, issue.1, pp.8-15, 2003.
DOI : 10.1016/S0302-2838(03)00201-X

M. Tinzl, M. Marberger, S. Horvath, and C. Chypre, DD3 RNA Analysis in Urine ? A New Perspective for Detecting Prostate Cancer, European Urology, vol.46, issue.2, pp.182-188, 2004.
DOI : 10.1016/j.eururo.2004.06.004

Y. Fradet, F. Saad, A. Aprikian, J. Dessureault, M. Elhilali et al., uPM3, a new molecular urine test for the detection of prostate cancer, Urology, vol.64, issue.2, pp.311-316, 2004.
DOI : 10.1016/j.urology.2004.03.052

M. Van-gils, D. Hessels, O. Van-hooij, S. Jannink, W. Peelen et al., The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance, Clinical Cancer Research, vol.13, issue.3, pp.939-982, 2007.
DOI : 10.1158/1078-0432.CCR-06-2679

I. Deras, S. Aubin, A. Blase, J. Day, S. Koo et al., PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome, The Journal of Urology, vol.179, issue.4, pp.1587-92, 2008.
DOI : 10.1016/j.juro.2007.11.038

G. Ploussard and A. De-la-taille, Test urinaire PCA3 en pratique clinique, Progr??s en Urologie - FMC, vol.19, issue.3, pp.86-90, 2009.
DOI : 10.1016/j.fpurol.2009.06.001

M. Van-gils, D. Hessels, C. Hulsbergen-van-de-kaa, J. Witjes, C. Jansen et al., Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results, The Prostate, vol.17, issue.11, pp.1215-1237, 2008.
DOI : 10.1002/pros.20781

P. Beuzeboc, M. Soulié, and P. Richaud, G??nes de fusion et cancer de la prostate. De la d??couverte ?? la valeur pronostique et aux perspectives th??rapeutiques, Progr??s en Urologie, vol.19, issue.11, pp.819-843, 2009.
DOI : 10.1016/j.purol.2009.06.002

X. Durand, E. Xylinas, G. Ploussard, D. La-taille, and A. , Biomarqueurs urinaires du cancer de prostate, Progr??s en Urologie, vol.20, issue.13, pp.1184-91, 2010.
DOI : 10.1016/j.purol.2010.07.017

B. Delongchamps, N. Bories, P. Younes, and P. , D??tection combin??e des g??nes de fusion TMPRSS2-ERG dans l???urine et le liquide de rin??age du pistolet ?? biopsies de la prostate, Progr??s en Urologie, vol.23, issue.13, pp.1041-1043, 2013.
DOI : 10.1016/j.purol.2013.08.057

L. Salomon, Le score de Gleason pour les nuls, Progr??s en Urologie - FMC, vol.24, issue.1, pp.13-15, 2014.
DOI : 10.1016/j.fpurol.2013.06.004

C. Bastide, P. Beuzeboc, and G. Ploussard, Recommandations en onco-urologie 2013 du CCAFU: Cancer de la prostate, Progrès en Urologie, vol.23, pp.67-101, 2013.

C. Bastide, P. Beuzeboc, L. Cormier, G. Fromont, C. Hennequin et al., Recommandations en onco-urologie 2013 du CCAFU: Cancer de la prostate, Prog Urol, vol.23, pp.67-101, 2013.

N. Mottet and J. Irani, Place de la surveillance active dans le cancer de la prostate: présentation du protocole français: Active surveillance in prostate cancer: the French protocol, Prog Urol, vol.18, issue.4, pp.12-16, 2008.

P. Albertsen, J. Hanley, and J. Fine, 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer, JAMA, vol.293, issue.17, pp.2095-101, 2005.
DOI : 10.1001/jama.293.17.2095

L. Site-de and . Has, Détection précoce du cancer de la prostate : actualisation du référentiel de pratiques de l'examen périodique de santé (EPS). [cité 17, 2014.

. Disponible-sur, has-sante.fr/portail/upload/docs/application/pdf/2013- 07/referentieleps_format2clic_kc_prostate_vfinale.pdf 36. Gross E. Radiothérapie conformationelle du cancer de prostate, Prog Urol, vol.21, issue.11, pp.801-808, 2011.

. Arcthérapie-dynamique and . Collimateur-multilame, OBI, radiothérapie avec modulation d'intensité, imagerie portale

. Disponible-sur, radiotherapie-lyon-macon.fr/lyon/equipements-oncologielyon .asp?idcat=2 38

. Disponible-sur, lurologie-grandpublic/fiches-patient/resultatsde-la-recherche/html/curietherapie-de-la-prostate .html?type=123 39. Association Francaise d'urologie. HIFU traitement du cancer de la prostate par ultrasons focalisés de haute intensité, 2012.

C. Bastide, F. Bruyère, and G. Karsenty, Le traitement hormonal du cancer de la prostate, Progr??s en Urologie, vol.23, issue.15
DOI : 10.1016/j.purol.2013.08.325

. Pharmacorama-hormone-hypothalamique, Disponible sur: http://www.pharmacorama.com/Rubriques/Output/Hormones_antehypophysairesa3.ph p 42. FIRMAGON 80mg poudre pour solution injectable -Monographie spécialité. [cité 22 août 2014]. Base de données médicamenteuses Thériaque. Disponible sur: http://www.theriaque.org/apps/monographie/index.php?type=SP&id=25047 43, Disponible sur, 2014.

B. Tombal, Quand est-ce que je propose un blocage androg??nique complet???, Progr??s en Urologie - FMC, vol.20, issue.1, pp.2-5, 2010.
DOI : 10.1016/j.fpurol.2009.09.003

H. Akaza, S. Hinotsu, M. Usami, Y. Arai, H. Kanetake et al., Combined androgen blockade with bicalutamide for advanced prostate cancer, Cancer, vol.174, issue.15, pp.3437-3482, 2009.
DOI : 10.1002/cncr.24395

L. Yin, Q. Hu, and R. Hartmann, Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer, International Journal of Molecular Sciences, vol.73, issue.03_MeetingAbstracts, pp.13958-78, 2013.
DOI : 10.1158/0008-5472.CAN-12-3630

C. Philippe, Pathophysiology of bone metastases and new molecular targets involved in bone remodelling, Bulletin du Cancer. nov, vol.100, issue.11, pp.1083-91, 2013.

P. Clézardin, Physiopathology of bone metastases, Oncologie, vol.11, issue.1, pp.10-15, 2009.
DOI : 10.1007/s10269-008-0977-1

J. Cornu and O. Cussenot, Biologie mol??culaire de la prostate??normale et pathologique, EMC - Urologie, vol.4, issue.2, pp.1-10, 2011.
DOI : 10.1016/S1762-0953(11)46413-X

B. Paule, Le concept d'hormonorésistance revisité dans le cancer de la prostate métastatique: implications thérapeutiques, Prog Urol, vol.14, pp.1119-1143, 2004.

N. De-la-taille-alexandre, J. Mottet, M. Bellmunt, and . Bolla, Mécanisme moléculaire du cancer de la prostate hormonorésistant Disponible sur: http://urologie-chumondor .aphp.fr/_recherche/tu_prost/mec_mol_echapp.htm 55 Guidelines on prostate Cancer. Part II : treatment of advanced, relapsing, and castration-resistant prostate cancer. European Association of urology, pp.572-83, 2011.

S. Geary and A. Salem, Prostate cancer vaccines, OncoImmunology, vol.53, issue.5, p.24523
DOI : 10.1016/S0360-3016(01)01692-3

L. Mansi, A. Thiery-vuillemin, E. Kalbacher, T. Nguyen, T. Maurina et al., immunothérapie: une nouvelle approche dans La prise en charge du cancer de prostate résistant à la castration, Bulletin du cancer, vol.99, pp.57-65

R. Madan, M. Bilusic, C. Heery, J. Schlom, and J. Gulley, Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines, Seminars in Oncology, vol.39, issue.3, pp.296-304, 2012.
DOI : 10.1053/j.seminoncol.2012.02.010

F. Site-de-la, Disponible sur: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts, Approved Products/ucm210215.htm 60. Provenge, Autologous peripheral blood mononuclear cells activated with PAP-GM- CSF (Sipuleucel-T). [cité 16 mai 2014], 2010.

H. Disponible-sur-kong and J. Byun, Emerging Roles of Human Prostatic Acid Phosphatase, Biomol Ther (Seoul). janv, vol.6221, issue.1, pp.10-20, 2013.

E. Cha and L. Fong, Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches, Journal of Clinical Oncology, vol.29, issue.27, pp.3677-85, 2011.
DOI : 10.1200/JCO.2010.34.5025

. Service-et-laboratoire-d-'hématologie-leucaphérèse-chuv-lausanne, Suisse [cité 16 janv 2015] Disponible sur: http://www.hematologie.chuv.ch/hem_home/hemprofessionnels/hem-pro-transplantation/hem-lexique/hem-pro-leucapherese .htm 65. Ouzaid I, Ravery V. Sipuleucel-T: un vaccin contre le cancer de la prostate:«mode d'emploi» pour les urologues, Prog Urol, vol.21, issue.9, pp.595-603, 2011.

C. Drake, Prostate cancer as a model for tumour immunotherapy, Nature Reviews Immunology, vol.14, issue.8, pp.580-93, 2010.
DOI : 10.4049/jimmunol.171.4.2161

B. Disponible-sur-singh, J. Gulley, P. Kantoff, C. Higano, N. Shore et al., dendreon.com/prescribing-information.pdf 68 Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, Asian J Androl New England Journal of Medicine, vol.69363, issue.5, pp.411-433, 2010.

P. Kantoff, T. Schuetz, and B. Blumenstein, Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1099-105, 2010.
DOI : 10.1200/JCO.2009.25.0597

R. Madan, P. Arlen, M. Mohebtash, J. Hodge, and J. Gulley, Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer, Expert Opinion on Investigational Drugs, vol.16, issue.7, pp.1001-1012, 2009.
DOI : 10.1158/1078-0432.CCR-07-5212

J. Gulley, P. Arlen, A. Bastian, S. Morin, J. Marte et al., Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer, Clinical Cancer Research, vol.11, issue.9, pp.3353-62, 2005.
DOI : 10.1158/1078-0432.CCR-04-2062

E. Abdalla, G. Blair, R. Jones, H. Sue-ling, and D. Johnston, Mechanism of Synergy of Levamisole and Fluorouracil: Induction of Human Leukocyte Antigen Class I in a Colorectal Cancer Cell Line, JNCI Journal of the National Cancer Institute, vol.87, issue.7, pp.489-96, 1995.
DOI : 10.1093/jnci/87.7.489

B. Fisk and C. Ioannides, Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity, Cancer Res. 1 nov, vol.58, issue.21, pp.4790-4793, 1998.

P. Arlen, J. Gulley, C. Parker, L. Skarupa, M. Pazdur et al., A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1260-1269, 2006.
DOI : 10.1158/1078-0432.CCR-05-2059

. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer, J Urol. août, vol.174, issue.2, pp.539-585, 2005.

M. Alegre, K. Fraurwirth, and C. Thompson, T-cell regulation by CD28 and CTLA-4, Nature Reviews Immunology, vol.405, issue.3, pp.220-228, 2001.
DOI : 10.1038/35011091

E. Ileana, S. Champiat, and J. Soria, Immune-Checkpoints : les nouvelles i mmunothérapies anticancéreuses YERVOY 5mg/mL solution injectable -Monographie spécialité, Base de données médicamenteuses Thériaque.Disponible sur, pp.601-611, 2013.

. Disponible-sur, Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer ClinicalTrials

P. Ascierto, R. Addeo, G. Cartenì, D. B. , D. Laurentis et al., The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014, Journal of Translational Medicine, vol.49, issue.suppl 2, 2014.
DOI : 10.1073/pnas.1016569108

S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, D. Smith et al., Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012.
DOI : 10.1056/NEJMoa1200690

J. Brahmer, L. Horn, J. Gandhi, D. Spigel, . Antonia et al., Nivolumab (anit-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small-cell lung cancer : survival and clinical activity by subgroup analysis, Journal of Clinical Oncology, vol.32, issue.5, p.2014, 2015.

I. Ouzaid, V. Ravery, D. Pouessel, and S. Culine, Nouvelles th??rapeutiques dans le cancer de la prostate r??sistant ?? la castration??: panorama des ??tudes pivotales et nouveaux sch??mas th??rapeutiques ?? venir, Progr??s en Urologie, vol.23, issue.1, pp.1-7, 2013.
DOI : 10.1016/j.purol.2012.07.007

C. Disponible-sur-ryan, M. Smith, J. De-bono, A. Molina, C. Logothetis et al., Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration- Resistant Prostate Cancer and No Prior Chemotherapy, N Engl J Med, vol.368, issue.2, pp.2012-04138, 2013.

M. Chan, R. Vialle, S. Thellier, B. Heuga, and J. P. Tasu, L'évaluation en oncologie : comment je fais en imagerie ? EM-Consulte, 2009.
DOI : 10.1016/s0181-9801(09)73601-2

D. Bono, J. Logothetis, C. Molina, A. Fizazi, K. North et al., Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011.
DOI : 10.1056/NEJMoa1014618

T. Hara, J. Kouno, T. Kaku, T. Takeuchi, M. Kusaka et al., 20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats, J Steroid Biochem Mol Biol. mars, vol.17134, pp.80-91, 2013.

J. Disponible-sur-persson and D. Semenas, Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Design 97. Enzalutamide, modalités pratiques d'utilisation d'une nouvelle hormonothérapie .Management of enzalutamide, a new hormonal therapy, Disponible sur, 2013.

A. Schrader, M. Boegemann, C. Ohlmann, T. Schnoeller, L. Krabbe et al., Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone, European Urology, vol.65, issue.1, pp.30-36, 2014.
DOI : 10.1016/j.eururo.2013.06.042

T. Beer, A. Armstrong, D. Rathkopf, Y. Loriot, C. Sternberg et al., Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014.
DOI : 10.1056/NEJMoa1405095

A. Abidi and . Cabazitaxel, Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects, Journal of Pharmacology and Pharmacotherapeutics, vol.4, issue.4, pp.230-237, 2013.
DOI : 10.4103/0976-500X.119704

A. Mita, L. Denis, E. Rowinsky, J. Debono, A. Goetz et al., Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.15, issue.2, pp.723-753, 2009.
DOI : 10.1158/1078-0432.CCR-08-0596

C. Paller and E. Antonarakis, Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer, Drug Des Devel Ther. 10 mars, vol.5, pp.117-141, 2011.

G. Russo, M. Mischi, W. Scheepens, and J. De-la-rosette, Angiogenesis in prostate cancer: onset, progression and imaging, BJU International, vol.45, issue.11c, pp.794-808, 2012.
DOI : 10.1097/RLI.0b013e3181ee8b83

A. Ravaud, Le mécanisme de l'angiogénèse tumorale, Prog Urol, vol.144, pp.1-5, 2007.

P. Lonergan and D. Tindall, Angiogenesis and anti-angiogenic therapy in prostate cancer, J Carcinog, vol.10, 1920.

Y. Li and P. Cozzi, Angiogenesis as a strategic target for prostate cancer therapy, Medicinal Research Reviews, vol.18, issue.1, pp.23-66, 2010.
DOI : 10.1016/j.urolonc.2004.08.013

N. Magne, C. Chargari, R. Conforti, R. Toillon, O. Bauduceau et al., Mécanismes de résistance aux thérapeutiques moléculaires ciblées dans le cancer du sein: constats et perspectives, Bulletin du cancer, vol.97, issue.3, pp.385-95, 2010.

W. Kelly, S. Halabi, M. Carducci, D. George, J. Mahoney et al., Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401, Journal of Clinical Oncology, vol.30, issue.13, pp.1534-1574, 2012.
DOI : 10.1200/JCO.2011.39.4767

I. Tannock, K. Fizazi, S. Ivanov, T. Karlsson, C. Fléchon et al., Re: Aflibercept versus Placebo in Combination with Docetaxel and Prednisone for Treatment of Men with Metastatic Castration-Resistant Prostate Cancer (VENICE): A Phase 3, Double-Blind Randomised Trial, The Journal of Urology. mars, vol.191, issue.3, pp.656-663, 2014.

Á. Pinto, Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma, Cancer Chemotherapy and Pharmacology, vol.19, issue.11, pp.219-241, 2014.
DOI : 10.1158/1078-0432.CCR-13-0319

R. Lee and M. Smith, Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer, The Cancer Journal, vol.19, issue.1, pp.90-98, 2013.
DOI : 10.1097/PPO.0b013e318281e280

I. Elixis, Elixis announce Results from the comet-1 phase 3 Pivotal Trail of cabozantinib in men with CRPC, 2014.

S. Williamson, A. Hartley, and R. Heer, A review of tasquinimod in the treatment of advanced prostate cancer, Drug Des Devel Ther, vol.7, pp.167-74, 2013.

N. Gupta, O. Ustwani, L. Shen, and R. Pili, Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer, OncoTargets and therapy. fevrier, vol.7, pp.223-257, 2014.

O. Bratt, M. Häggman, G. Ahlgren, . Nordle-Ö, A. Björk et al., Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer, British Journal of Cancer, vol.143, issue.8, pp.1233-1273, 2009.
DOI : 10.1056/NEJMoa040720

S. Osanto, H. Van-poppel, and J. Burggraaf, Tasquinimod: a novel drug in advanced prostate cancer, Future Oncology, vol.52, issue.9, pp.1271-81, 2013.
DOI : 10.1016/j.jchromb.2011.09.013

T. Koltai, Clusterin: a key player in cancer chemoresistance and its inhibition, OncoTargets and Therapy, vol.447, 2014.
DOI : 10.2147/OTT.S58622

C. Higano, Potential use of custirsen to treat prostate cancer, OncoTargets and Therapy, vol.6, pp.785-97, 2013.
DOI : 10.2147/OTT.S33077

P. Saylor, Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer, Asian Journal of Andrology, vol.16, issue.3, p.341, 2014.
DOI : 10.4103/1008-682X.122591

K. Fizazi, M. Carducci, M. Smith, and . Damiao, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, The Lancet, vol.377, issue.9768, pp.813-835, 2011.
DOI : 10.1016/S0140-6736(10)62344-6

M. Smith, R. Saad, N. Coleman, and . Shore, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, The Lancet, vol.379, issue.9810, pp.39-46, 2012.
DOI : 10.1016/S0140-6736(11)61226-9

J. Cheetham and D. Petrylak, Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases: Mechanism of Action of Radium-223 Chloride (Alpharadin) and Radiation | Cancer Network, Oncology Journal. 17 avr, 2012.

C. Parker, S. Nilsson, D. Heinrich, S. Helle, O. Sullivan et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013.
DOI : 10.1056/NEJMoa1213755

F. Site-de-la, FDA approves new drug for advanced prostate cancer, Disponible sur, 2014.

G. Pignot, Cancer de prostate résistant à la castration : quelle prise en charge en 2014 ? Progrès en Urologie -FMC, pp.73-82, 2014.
DOI : 10.1016/j.fpurol.2014.05.003

H. Echo, S. Dominique, and V. Ravery, Dépistage du cancer de la prostate : les arguments « pour ». Annales d'urologie, pp.179-83, 2006.

M. Soulié and L. Salomon, Dépistage du cancer de la prostate : pourquoi, comment ? Revue du practicien, pp.469-79, 2013.

A. Villers, X. Rébillard, M. Soulié, J. Davin, P. Coloby et al., Dépistage du cancer de la prostate, Prog Urol, vol.209, 2003.

P. Perrin, Dépistage du cancer de la prostate : les arguments « contre ». Annales d'Urologie, avr, vol.40, issue.2, pp.101-106, 2006.
DOI : 10.1016/j.mednuc.2007.11.005

F. Schröder, J. Hugosson, M. Roobol, T. Tammela, M. Zappa et al., Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, The Lancet, vol.384, issue.9959, pp.2027-2062, 2014.
DOI : 10.1016/S0140-6736(14)60525-0

J. Hugosson, S. Carlsson, G. Aus, S. Bergdahl, A. Khatami et al., Mortality results from the G??teborg randomised population-based prostate-cancer screening trial, The Lancet Oncology, vol.11, issue.8, pp.725-757, 2010.
DOI : 10.1016/S1470-2045(10)70146-7

A. Bill-axelson, L. Holmberg, H. Garmo, J. Rider, K. Taari et al., Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer, New England Journal of Medicine, vol.370, issue.10, pp.932-974, 2014.
DOI : 10.1056/NEJMoa1311593

C. Jichlinski and P. , Dépistage du cancer de la prostate : utilité, buts et perspectives en 2010, Urologie. 8 déc, vol.274, issue.44, pp.2336-2345, 2010.